Oveporexton - The First Orexin Receptor Activator
April 4, 2026
1,365
67
14
5.93%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Kruse Episodes Around April 4, 2026
See what was published immediately before and after this episode.
18:28Now PlayingOveporexton - The First Orexin Receptor Activator
Chapters
YouTube Description
as posted by the channelMain Chapters:
Orexin is a polypeptide neurotransmitter intimately involved in regulating wakefulness and sleep. Belsomra, Dayvigo, and Quviviq are orexin receptor blockers used to treat insomnia, and some of modafinil/Provigil's actions seem to come from activating orexin neurons in the hypothalamus. The most common type of narcolepsy derives from destruction of these orexin neurons, and now Takeda Pharmaceuticals is on the verge of gaining FDA approval of the orexin receptor activator, oveporexton, to treat narcolepsy. Study results indicate that oveporexton increases daytime wakefulness, improves sleep, and decreases other symptoms of narcolepsy. Given the extensive symptom overlap between ADHD and narcolepsy, some day orexin agonists may be used for treating ADHD.
-----
Free link to my Medium article on Oveportexton:
Follow on Medium for hundreds of full length articles on this subject and more!
Access to Full Medium articles requires paid membership.
-----
References:
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 (2025)
Effects of Oveporexton, an Orexin Receptor 2–Selective Agonist, on Cognition in Narcolepsy Type 1 A Secondary Analysis of a Randomized Clinical Trial (2025)
A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1 (2025) Xu et al
Dysregulation of the orexin–leptin–ghrelin axis and its associations with chronotype and sleep disturbances in drug-naïve children with ADHD (2025)
TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models (2024)
Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone (2022)
Modafinil and orexin system: interactions and medico-legal considerations (2019)
Differential Roles of Orexin Receptors in the Regulation of Sleep/Wakefulness (2013)
Full Chapter list:
-------------------------
Psychiatrist, neuroscientist, and author John Kruse, MD, PhD presents practical, actionable, well-researched information about treatment options that scientists and clinicians recommend for adult ADHD and other mental health conditions.
Subscribe if you're curious about how neuroatypical brains can optimize their functioning in our shared, and somewhat strange, world.
ADHD topics have a pink background, and those on more general mental health topics have a purple background. A small collection of Politics related videos have an orange background.
Dr. Kruse has posted videos in the "Videos", "Live", and "Shorts", sections of this channel.
You're welcome to email him with topics you want discussed or people you think he should interview.
drjohnkruse@gmail.com
#health #mentalhealth #adhd #orexin
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.